Skip to main content

Advertisement

SpringerLink
Log in

The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Vascular endothelial growth factor (VEGF) is known to be involved in the pathogenesis of rheumatoid arthritis (RA). In order to elucidate the association between VEGF levels and RA disease activity, VEGF concentrations were measured in RA patients at different phases and severity levels. Thirty-eight healthy subjects and 40 patients with RA were prospectively included in the study. Subjects were further categorized into four subgroups (high, moderate, low, or remission) using the disease activity score-28 (DAS28) scoring system. VEGF levels were significantly higher in patients than controls (p < 0.001). VEGF levels differed significantly in controls, early and late-phase RA patients (p = 0.002). A significant difference was found between controls and patients with high RA disease activity scores (p < 0.0001). VEGF levels were not correlated with age (r = −0.016; p = 0.921) or sex (r = 0.209; p = 0.921). VEGF values were correlated with erythrocyte sedimentation rate (r = 0.445; p = 0.004), but was not correlated with serum rheumatoid factor levels (r = −0.130; p = 0.424) in the patient group. In conclusion, higher VEGF levels are associated with late phase and high disease activity in RA, independent of age and sex.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Koch AE, Harlow LA et al (1994) Vascular endothelial growth factor A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152:4149–4156

    CAS  PubMed  Google Scholar 

  2. Fava RA, Olsen NJ et al (1994) Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346

    Article  CAS  PubMed  Google Scholar 

  3. Kikuchi K, Kubo M et al (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051

    Article  CAS  PubMed  Google Scholar 

  4. Harada M, Mitsuyama K et al (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumalol 27:377–380

    Article  CAS  Google Scholar 

  5. Paleolog EM (2009) The vasculature in rheumatoid arthritis: cause or consequence. Int J Exp Pathol 90(3):249–261

    CAS  PubMed  Google Scholar 

  6. Yoo SA, Kwok SK, Kim WU (2008) Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm Epub 2008:129873

    Google Scholar 

  7. Sone H, Sakauchi M et al (2001) Elevated levels of vascular endothelial growth factor in the sera of patients with rheumatoid arthritis correlation with disease activity. Life Sci 69:1861–1869

    Article  CAS  PubMed  Google Scholar 

  8. Ballara S, Taylor PC et al (2001) Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44:2055–2064

    Article  CAS  PubMed  Google Scholar 

  9. Lee SS, Joo YS et al (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324

    CAS  PubMed  Google Scholar 

  10. Latour F, Zabraniecki L et al (2001) Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study in 12 patients monitored for 10 years. Joint Bone Spine 68:493–498

    Article  CAS  PubMed  Google Scholar 

  11. Klimiuk PA, Sierakowski S et al (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809

    Article  CAS  PubMed  Google Scholar 

  12. Drouart M, Saas P et al (2003) High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 132:158–162

    Article  CAS  PubMed  Google Scholar 

  13. Strunk J, Heinemann E, Neeck G, Schmidt KL, Lange U (2004) A new approach to studying angiogenesis in rheumatoid arthritis by means of power Doppler ultrasonography and measurement of serum vascular endothelial growth factor. Rheumatology (Oxford) 43:1480–1483

    Article  CAS  Google Scholar 

  14. Ardicoglu O, Boz K et al (2004) Levels of vascular endothelial growth factor in patients with rheumatoid arthritis. The Pain Clinic 16:187–191

    Article  Google Scholar 

  15. Pinheiro GR, Andrade CA et al (2001) Serum vascular endothelial growth factor in late rheumatoid arthritis. Clin Exp Rheumatol 19:721–723

    CAS  PubMed  Google Scholar 

  16. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M (2005) A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol 25:314–319

    Article  PubMed  Google Scholar 

  17. Clavel G, Bessis N et al (2007) Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction. Clin Immunol 124:158–164

    Article  CAS  PubMed  Google Scholar 

  18. Choi ST, Kim JH, Seok JY, Park YB, Lee SK (2009) Therapeutic effect of anti-vascular endothelial growth factor receptor I antibody in the established collagen-induced arthritis mouse model. Clin Rheumatol 28(3):333–337

    Article  PubMed  Google Scholar 

  19. Taylor PC (2005) Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology(Oxford) 44(6):721–728

    Article  CAS  Google Scholar 

  20. Firestein GS (1999) Starving the synovium:angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest 103:3–4

    Article  CAS  PubMed  Google Scholar 

  21. Smolen JS, Breedveld FC et al (2003) A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 42(2):244–257

    Article  CAS  PubMed  Google Scholar 

  22. Hormbrey E, Gillespie P et al (2002) A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood. Is the current literature meaningful. Clin Exp Metastasis 19(8):651–663

    Article  CAS  PubMed  Google Scholar 

  23. Costa C, Incio J, Soares R (2007) Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10(3):149–166

    Article  PubMed  Google Scholar 

  24. Paleolog EM, Young S et al (1998) Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 41(7):1258–1265

    Article  CAS  PubMed  Google Scholar 

  25. Nagashima M, Wauke K et al (2000) Effects of combination of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 39:1255–1262

    Article  CAS  Google Scholar 

  26. Pandya NM, Dhalla NS, Santani DD (2006) Angiogenesis—a new target for future therapy. Vascul Pharmacol 44:265–274

    Article  CAS  PubMed  Google Scholar 

  27. Kurosaka D, Hirai K et al (2009) Correlation between synovial blood flow signals and serum vascular endothelial growth factor levels in patients with refractory rheumatoid arthritis. Mod Rheumatol 19(2):187–191

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None

Author information

Authors and Affiliations

  1. Ministry of Health, Istanbul Research and Training Hospital, Physical Medicine and Rehabilitation Clinic, Istanbul, Turkey

    Levent Ozgonenel, Esra Cetin & Sule Tutun

  2. Ministry of Health, Istanbul Research and Training Hospital, Biochemistry Laboratory, Istanbul, Turkey

    Pinar Tonbaklar, Hale Aral & Guvenc Guvenen

Authors
  1. Levent Ozgonenel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esra Cetin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sule Tutun
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pinar Tonbaklar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hale Aral
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Guvenc Guvenen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Levent Ozgonenel.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ozgonenel, L., Cetin, E., Tutun, S. et al. The relation of serum vascular endothelial growth factor level with disease duration and activity in patients with rheumatoid arthritis. Clin Rheumatol 29, 473–477 (2010). https://doi.org/10.1007/s10067-009-1343-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1343-4

Keywords

Search

Navigation